Search

Your search keyword '"Ghesquières, Hervé"' showing total 460 results

Search Constraints

Start Over You searched for: Author "Ghesquières, Hervé" Remove constraint Author: "Ghesquières, Hervé" Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
460 results on '"Ghesquières, Hervé"'

Search Results

1. High-dose chemotherapy with autologous haematopoietic stem cell transplantation in patients with isolated vitreoretinal lymphoma: a LOC network study

2. Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling

3. Classic Hodgkin Lymphoma: The LYSA pragmatic guidelines

4. Autologous stem cell transplantation in T-cell/histiocyte-rich large B-cell lymphoma: EBMT Lymphoma Working Party study

5. Health-related quality of life profile of newly diagnosed patients with Hodgkin and non-Hodgkin lymphomas: A real-world study including 3922 patients from the French REALYSA cohort

6. A quick access to information on influenza burden and prevention in Lyon university hospital: A prospective QR code-based information campaign in 2022–2023

7. The phase 2 LYSA study of prednisone, vinblastine, doxorubicin, and bendamustine for untreated Hodgkin lymphoma in older patients

8. Challenges for quality and utilization of real-world data for diffuse large B-cell lymphoma in REALYSA, a LYSA cohort

9. Brentuximab vedotin with AVD for stage II–IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial

10. Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes

11. HLA-DR expression on monocytes and outcome of anti-CD19 CAR T-cell therapy for large B-cell lymphoma

12. BTG1 inactivation drives lymphomagenesis and promotes lymphoma dissemination through activation of BCAR1

13. Correction: Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes

14. Genetic overlap between autoimmune diseases and non‐Hodgkin lymphoma subtypes

15. Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trial

17. Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life—experience of the French Network

18. End-of-life management of multiple myeloma patients in the era of CD38 and immunotherapy.

19. Hodgkin Lymphoma, Classical

21. Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified

22. Incidence of central nervous system relapses in patients with DLBCL treated with lenalidomide as maintenance after R-CHOP

23. IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma

24. Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes

25. Impact on Outcome of Minimal Residual Disease after Hematopoietic Stem Cell Transplantation with Fludarabine, Amsacrine, and Cytosine Arabinoside-Busulfan Conditioning: A Retrospective Monocentric Study

26. A French multicentric prospective prognostic cohort with epidemiological, clinical, biological and treatment information to improve knowledge on lymphoma patients: study protocol of the “REal world dAta in LYmphoma and survival in adults” (REALYSA) cohort

27. Plasticity of Mature B Cells Between Follicular and Classic Hodgkin Lymphomas: A Series of 22 Cases Expanding the Spectrum of Transdifferentiation

28. Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling

29. Retrospective multicenter comparative study of the efficacy and safety between R-DHAC and R-DHAOx in diffuse large B-cell lymphoma or transformed follicular or marginal zone B lymphoma into aggressive lymphoma, as a second-line treatment

30. ANTIFON-CLIC®, a new clinical decision support system for the treatment of invasive aspergillosis: is it clinically relevant?

32. ABCL-422 Subcutaneous Epcoritamab in Patients With Relapsed or Refractory Large B-Cell Lymphoma (EPCORE NHL-1): Pivotal Results from a Phase 2 Study

34. Brentuximab vedotin with AVD for stage II–IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial

35. Long-lasting CRs after ibrutinib monotherapy for relapse or refractory primary CNS lymphoma (PCNSL) and primary vitreoretinal lymphoma (PVRL): Long-term results of the iLOC study by the Lymphoma Study Association (LYSA) and the French Oculo-Cerebral Lymphoma (LOC) Network (clinical trial number: NCT02542514)

36. Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma

38. Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group

39. Retrospective multicenter comparative study of the efficacy and safety between R-DHAC and R-DHAOx in diffuse large B-cell lymphoma or transformed follicular or marginal zone B lymphoma into aggressive lymphoma, as a second-line treatment.

40. Normal B cells express ZAP70 in chronic lymphocytic leukemia: A link between autoimmunity and lymphoproliferation?

43. Management and outcome of primary CNS lymphoma in the modern era: An LOC network study

44. Brentuximab-vedotin in combination with cyclophosphamide, doxorubicin, prednisolone for the treatment of aggressive CD30-positive cutaneous T-cell lymphomas

45. Correction: Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes

46. Correction: Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes

47. Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial

48. Gray-zone Lymphoma Between cHL and Large B-Cell Lymphoma: A Histopathologic Series From the LYSA

49. Supplementary Table 1 from Recurrent Mutations of MYD88 and TBL1XR1 in Primary Central Nervous System Lymphomas

50. Data from HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes

Catalog

Books, media, physical & digital resources